Background. Biomarkers used at the time of diagnosis to tailor treatment decisions may diffuse into clinical practice before data become available on whether biomarker testing reduces cancer mortality. In the interim, quantitative estimates of the mortality impact of testing are needed to assess the value of these diagnostic biomarkers. These estimates are typically generated by customized models that are resource intensive to build and apply. Methods. We developed a user-friendly system of models for Cancer Translation of Comparative Effectiveness Research (CAN-TRANce) to model the mortality impact of cancer interventions. The Diagnostic Biomarker module of this system projects the mortality impact of testing for a diagnostic biomarker, given data on how testing affects treatment recommendations. Costs and quality-of-life outcomes may also be modeled. We applied the Diagnostic Biomarker module to 2 case studies to demonstrate its capabilities. Results. The user interface (http://www.fhcrc.org/cantrance) allows comparative effectiveness researchers to use the Diagnostic Biomarker module of CANTRANce. Our case studies indicate that the model produces estimates on par with those generated by customized models and is a strong tool for quickly generating novel projections. Limitations. The simple structure that makes CANTRANce user-friendly also constrains the complexity with which cancer progression can be modeled. The quality of the results rests on the quality of the input data, which may pertain to small or dissimilar populations or suffer from informative censoring. Conclusions. The Diagnostic Biomarker module of CANTRANce is a novel public resource that can provide timely insights into the expected mortality impact of testing for diagnostic biomarkers. The model projections should be useful for understanding the long-term potential of emerging diagnostic biomarkers. Key words: decision analysis; breast cancer; outcomes research; comparative effectiveness; simulation methods. (Med Decis Making 2016;36:594-603) O ver the past decade, advances in genomic research have produced biomarkers to target cancer treatments to a patient's unique molecular characteristics. [1] [2] [3] [4] Testing patients for biomarkers that either predict response to particular cancer therapies or supply prognostic information can support tailored treatment decisions that improve outcomes and/or reduce toxicity. Established examples of such biomarkers include the Her-2/ Neu oncogene that predicts a positive response to trastuzumab for breast cancer and the KRAS mutations that indicate resistance to anti-epidermal growth factor receptor treatments for metastatic colorectal cancer. 5 In both of these examples, randomized controlled trials (RCTs) of patients who are positive for the biomarkers in question have demonstrated better survival with tailored treatment. 4, [6] [7] [8] [9] [10] In contrast, emerging biomarkers may diffuse into clinical practice long before survival data become available. Depending on the cancer, more than a decade may pass between early-stage studies of a diagnostic biomarker and an RCT that confirms the benefit of testing and tailored treatment on survival, if such a study is even done. 11 In the interim, comparative effectiveness (CE) studies typically collect data on how testing for a biomarker affects an intermediate endpoint such as treatment recommendations. [12] [13] [14] [15] [16] [17] While data on treatment recommendations can suggest that testing has affected treatment, these data do not address the ultimate question of whether testing reduces cancer mortality.
Quantitative estimates of the mortality impact of testing are needed to assess the value of these biomarkers, which we will call ''diagnostic biomarkers'' given their use at the time of diagnosis to inform treatment choices. One way to meet this need is to conduct a complementary modeling study that translates changes in treatment recommendations into projected effects on mortality. This strategy of using models for comparative effectiveness research (CER) when observational data are unavailable has been highlighted as both important and underutilized in cancer research. 18, 19 Moreover, the fast pace of biomarker development has created a demand for CER that cannot be fully met by observational studies: when competing diagnostic biomarkers emerge, there may be more head-to-head comparisons than can be feasibly investigated. This environment is a perfect opportunity for modeling to supply otherwise unattainable CE results.
A practical obstacle to modeling the impact of diagnostic biomarkers is that the investigators who conduct CE studies of how diagnostic biomarkers affect treatment typically do not have the additional resources to conduct the complementary modeling study translating their results to mortality. On the other hand, research groups with modeling expertise often conduct modeling studies using aggregate data from the literature because they are not connected with investigators who have primary data. In addition, many modeling studies are highly application specific and customized to the particular question at hand, preventing them from being quickly reapplied as new diagnostic biomarkers emerge.
To address this gap, we have developed a system of statistical simulation models for Cancer Translation of Comparative Effectiveness Research (CAN-TRANce) that facilitates the modeling of the mortality impact of interventions, given CE studies of typical intermediate endpoints (i.e., the common premortality outcomes used to demonstrate the effectiveness of interventions). CANTRANce can model the mortality impact of several intervention-intermediate endpoint pairs: preventive interventions and disease incidence, screening tests and sensitivity and specificity of detection or stage distribution of detected cancers, diagnostic biomarkers and treatment distributions, and treatments and disease recurrence. Users enter data from a CE study of how an intervention affects an intermediate endpoint, and the modeling system prompts them for additional data from the literature or other studies. The system then extrapolates from the intermediate endpoint to the projected impact of the intervention on mortality. In this article, we introduce the Diagnostic Biomarker module of CANTRANce and use it to evaluate a diagnostic biomarker for breast cancer. We show how CANTRANce can flexibly model the impact of a new diagnostic biomarker on mortality as well as on quality-adjusted life-years (QALYs) and costs.
METHODS

CANTRANce Framework
In all CANTRANce models, we use an individuallevel microsimulation approach in which individuals transition through health states, and transitions occur in continuous time rather than at specified time intervals (see the supplemental Appendix A: Glossary of Terminology). 20, 21 The models simulate a virtual population and project outcomes for 2 scenarios: one in which individuals do receive the intervention and one in which they do not. The impact of the intervention on the intermediate endpoint is based on a CE study ending at that endpoint. We model each person's subsequent series of health states or ''life history'' by projecting the dates of key events such as disease progression and mortality. 20, 21 The Diagnostic Biomarker (Diagnostics) module of CANTRANce evaluates the impact of testing for a new diagnostic biomarker to target treatment ( individuals receive a one-time testing intervention using the diagnostic biomarker and 2) no individuals receive testing. The foundation for the model is a CE study of how the testing intervention affects the intermediate endpoint, treatment recommendations. Based on this CE study, the testing intervention and no-testing scenarios each have different distributions of 2 possible treatments: a standard treatment and a tailored treatment whose indication changes after test results are known. To project to mortality, the model prompts the user for the necessary additional information on expected cancer mortality following each treatment option. Alternatively, the user may project to mortality through a second intermediate endpoint of disease recurrence.
The precise inputs and steps involved in the projection depend on certain choices available to the user. These elements are described in detail below from the perspective of a user running the model via the user-friendly Windows application interface, downloadable from http://www.fhcrc.org/cantrance. The interface prompts the user for the necessary inputs and then runs the model locally using an open-source R package, cantrance (v 1.1). The results and open-source code for the model are stored on the user's local machine.
General Modeling Selections
The user must specify the number of simulations and years at which to evaluate survival. Each simulation represents 1 study linking testing to treatment and mortality, and multiple simulations capture the stochastic uncertainty due to the simulation process. 22 Users can also define multiple follow-up time points for the projection (e.g., 10-y as well as lifetime follow-up).
Constructing the Virtual Population
The Diagnostics model begins by generating a virtual population that mimics the population in the CE study. At minimum, each individual in the virtual population needs to be assigned a gender, age at treatment, and either 1) treatment recommended under the testing intervention versus under no testing, for paired CE studies in which treatment was assessed for the same patients under both scenarios, or 2) treatment recommended and an intervention indicator, for unpaired CE studies in which the testing intervention versus no testing was studied using different patients. Other relevant covariates may also be included. The 2 options for generating this population are as follows.
Specify covariate summaries. If the user has only population-level summary statistics for covariates reported in the CE study publication, the Diagnostics model can use those to generate a virtual study population for each simulation in which individuals have covariate values that are consistent with the published data at the population level. Both marginal and joint distributions of categorical and continuous covariates can be accommodated. The Diagnostics model will assume independence between covariates without specified joint distributions.
Bootstrap from individual-level data. If individuallevel data from the CE study are available to the user, the entire CE study population can be entered into the model. For each simulation, the model will bootstrap from this population to define the virtual study population. Bootstrapping preserves all the interrelations between covariates in the original study. While the default bootstrap is unweighted, the user may alternatively specify weights for the resampling in order to model the impact of testing on a population with a particular covariate distribution.
Modeling Treatment Received
The virtual population includes an indicator of treatment recommended under each scenario, and this value can be used directly. Alternatively, if individuallevel data are available, the user may choose to run a logistic regression of treatment received, separately for each scenario, based on available predictors in the data. For the testing intervention scenario, the test result is a required predictor. In each simulation, CANTRANce fits the regression and uses the results to simulate treatment recommended under each scenario. If the CE study is very small, the regression-based treatment distributions for the virtual population may be more stable than the observed values.
Modeling Time from Treatment to Mortality
This step projects the dates of cancer and othercause mortality for each virtual individual. The cause of death is determined by the event that occurs first.
The Diagnostics model projects times to event using a single, user-specified survival statistic (e.g., an event rate or k-year survival). This statistic is translated into an exponential survival curve from which the model simulates times to event for each individual. Hazard ratios may be specified to modify this curve for particular covariate values.
It is important to note that the survival statistic is interpreted as a net statistic, that is, in the absence of other-cause death (supplemental Appendix A: Glossary of Terminology). Users may find some net statistics reported directly in the literature. In particular, relative survival is an appropriate net statistic 23 routinely reported by Surveillance, Epidemiology and End Results (SEER) Cancer Statistics Review. 24 The SEER database 25 provides another venue for deriving net survival statistics. Alternatively, a composite statistic such as overall survival or disease-free survival can be used to approximate a net statistic when the risk of death from other causes is relatively low in the study cohort (e.g., in a younger cohort).
The user may choose to use disease recurrence as an intermediate endpoint within the time to mortality projection. If so, the Diagnostics model requires one survival statistic for the time from treatment to recurrence and another statistic for time from recurrence to mortality. Otherwise, the user specifies one survival statistic describing time from treatment to mortality. In either case, the user must specify at least one hazard ratio describing the benefit of tailored versus standard treatment on the event (recurrence and/or mortality). Additional hazard ratios may be specified if survival or the benefit of tailored treatment varies by other covariates.
Age at other-cause death is simulated from US cohort life tables. 26 A hazard ratio on the life table may be specified if the CE study population is thought to have all-cause survival that differs from the general population. 27
Modeling Quality of Life and Cost
Because some diagnostic biomarkers primarily function to spare patients unnecessary treatment and thus improve quality of life, the Diagnostics model also allows users to specify annual costs and utility weights for key periods during the life history: the first year of treatment, subsequent years until mortality, and the year of death. If recurrence is used in modeling survival, cost and utilities can be further partitioned by the onset of recurrence. All costs and utility weights can vary by tailored versus standard treatment. The user may also specify a discount rate to discount future gains to their present value. 28 
Quantifying Uncertainty
Each run of the Diagnostics model performs multiple simulations using the same parameter set. 20 Stochastic (i.e., Monte Carlo) uncertainty is quantified by summarizing results across simulations using the mean as the point estimate and the 2.5% and 97.5% quantiles as the 95% uncertainty interval. Sensitivity to parameter values can be easily investigated by changing parameters through the user interface. Formal one-way and probabilistic sensitivity analyses that systematically investigate parameter sets are also possible outside of the interface, using some customized R programming. For sensitivity analyses, we again describe uncertainty using the 2.5% and 97.5% quantiles across runs to define the 95% uncertainty interval.
Case Studies
The Diagnostics model is designed to be a highquality, flexible tool to project long-term outcomes following testing with a diagnostic biomarker. We developed 2 case studies that highlight these features. The first case compares the Diagnostics model's performance to that of a previously developed customized model, and the second case provides novel CE projections in a setting where there is no existing model.
Both cases are founded on CE studies of how a testing intervention using a 21-gene recurrence score (RS) for breast cancer affects treatment recommendations for adjuvant chemotherapy plus hormone therapy (tailored treatment) versus hormone therapy alone (standard treatment). The RS classifies patients as being at low, intermediate, or high risk of disease recurrence. The CE studies describe how physician treatment recommendations change with and without RS knowledge. The Diagnostics model translates these changes in treatment to their impact on mortality, QALYs, and costs. In both cases, we discount outcomes using the standard rate of 3%. 29
Case 1: Replication of a Customized Model
In case 1, we replicated projections made by a customized model developed by Reed and others 30 to compare using the RS to guide treatment (the testing intervention, or ''with RS'') to National Comprehensive Cancer Network guideline-based treatment (no testing, or ''without RS''). Reed and others 30 used a Markov cohort decision model to project outcomes for these 2 scenarios based on a published CE study in which medical oncologists made 2 treatment recommendations for node-negative, estrogen receptor (ER)-positive patients, first without the patients' RS and then with the RS. 12, 31 Because the model used published CE data, no individual-level data were available, and we thus used the covariate summaries option of the Diagnostics model to replicate the CE study population reported in Reed and others. 30 We projected time to mortality, total costs from the societal perspective, and QALYs using recurrence as a second intermediate endpoint (Table 1) . We additionally replicated the probabilistic sensitivity analysis (PSA) using the same standard errors and distributional assumptions ( Table 1) . As a sensitivity analysis, we investigated the impact of customizing the Diagnostics model to match the Reed model on 2 final elements: their period life table (versus our  cohort life table) and their assumption that recurrence is possible only in the first 10 y (versus our unlimited possibility of recurrence).
Case 2: Novel Projection of the Impact of Diagnostic Testing
In case 2, we did a novel projection of the impact of the RS using individual-level data from a CE study by Ademuyiwa and others 14 of how testing affected treatment recommendations in node-negative, ERpositive women. The CE study compared treatment recommendations made with RS knowledge (the testing intervention, or ''with RS'') to those made in a retrospective chart review in which the RS was withheld from the medical oncologist (no testing, or ''without RS''). In this case, the individual-level CE data were made available to us, so we used the individual-level CE data option to construct the virtual population and projected mortality, total costs, and QALYs using the same parameters as in case 1 ( Table 1) . We also performed a PSA using the same standard errors and distributional assumptions as in case 1.
Tutorial
To facilitate use of the Diagnostics model, we provide a tutorial in the supplemental appendix that shows how to replicate the case 1 and case 2 models through the user interface and provides additional technical details and modeling guidance. The tutorial also demonstrates how advanced users can access the R code. This written tutorial is accompanied by a video tutorial to familiarize users with the interface (http://www.fhcrc.org/cantrance). Because of data privacy restrictions, the case 2 replication in the tutorial uses a public-access approximation of the true individual-level data, generated from the information published in Ademuyiwa and others. 14 
RESULTS
User Interface
The interface for the Diagnostics model walks the user through each of the modeling steps outlined in the ''CANTRANce Framework'' section of the ''Methods'' section ( Figure 2) . The user specifies modeling choices in a scrolling left panel through a combination of selection boxes, user-defined tables, and numeric entry boxes. Individual-level CE data can be entered using a comma-separated text (.csv) file. Once the CE study data are entered, the left panel updates to reflect those data. The right panel of the interface allows the user to navigate between sections of the model, view help files, and run the model with a viewport to the R session.
Results of Case Studies
The CE studies used as inputs to the Diagnostics model for each case had different population ages and risk distributions ( Table 2 ). All case 1 patients were assumed to be 55 y old, following the Reed model. 30 The average age in case 2 was also 55 y, but ages ranged from 29 to 82 y. About half of patients were classified as low RS in both cases, but the case 2 data had very few high-RS patients compared with case 1.
Use of the RS decreased adjuvant chemotherapy among low-RS women and increased it among high-RS women in both samples. Case 1 data additionally indicated an increase in adjuvant therapy among intermediate-RS women with use of the RS ( Table 2 ).
The models for both CE studies projected that testing with the RS increases life-years and QALYs at reasonable cost but with substantial uncertainty ( Table  3 ). Benefits of using the RS were greater for the case 1 models because of the greater proportion of highrisk patients in the population, for whom use of chemotherapy increased from 67% to 100% in case 1 versus the smaller increase of 88% to 96% in case 2 ( Table  2 ). In addition, more intermediate-RS women were switched onto chemotherapy with the RS in case 1 ( Table 2) , and this was modeled as beneficial for all of them (Table 1 ). In both the high-and intermediate-RS groups, the survival benefits of chemotherapy outweighed its negative impact on quality of life to result in QALYs gained on average. However, the additional courses of chemotherapy also resulted in greater incremental costs in case 1. In case 2, the primary effect of testing was to decrease chemotherapy in low-RS women ( Table 2) . Costs saved by avoiding unnecessary chemotherapy in case 2 almost completely offset the cost of testing, on average ( Table 3) .
The case 1 results projected greater incremental life-years and QALYs than those reported by Reed, Note: Distributional assumptions for probabilistic sensitivity analysis also follow from Reed and others 30 : beta distributions for probabilities and utilities, normal distributions for costs and log-relative risks, and Dirichlet for the multinomial parameters describing the comparative effectiveness study covariate summaries (not shown). RS = recurrence score. a. This is a composite statistic used to approximate the net statistic of time to recurrence. b. Standard error is on the log scale. c. Five-year annual costs of $105 for hormonal therapy, included by Reed and others, were not included. d. These costs were applied until recurrence occurred, whereas Reed and others limited them to 10 y. but in our sensitivity analysis, we were able to closely replicate the Reed results ( 
DISCUSSION
The Diagnostic Biomarker module of CANTRANce is a powerful new tool for understanding the likely impact of new diagnostic biomarkers to target cancer treatment. As a free, open-source modeling platform, it is a unique public resource to support timely CER on emerging diagnostic biomarkers. The userfriendly interface allows investigators to extend their CE results of how testing affects treatment to mortality, quality-adjusted mortality, and costs without needing to commission a customized model. This is made possible by the variety of modeling options available to the user within the Diagnostics model. The model can flexibly accommodate CE data in multiple forms as well as conform to various other user needs, such as the use of disease recurrence as a second intermediate endpoint. The user can also use the interface to easily investigate how altering model assumptions changes results. The availability of all these features in one model holds great potential for quick projections as CE studies of how emerging diagnostic biomarkers affect treatment become available. Head-to-head comparisons of competing diagnostic biomarkers may reveal expected differences-or a lack thereof-that can be used to prioritize further research.
The 2 case studies presented in this article validate the capability of the Diagnostics model to produce projections on par with customized models and provide a novel projection of the impact of testing with a diagnostic biomarker. The case 1 model closely replicated the Reed model once all assumptions were matched. The case 2 model suggested less benefit but also lower costs with testing than case 1. The different results for the 2 cases highlight that the projections can be sensitive to the CE study on which they are based. Case 1 projected greater benefit and costs than case 2 because of the different population risk distributions and the differences in the impact of testing indicated by the 2 CE studies. The interpretation and application of these projected outcomes must thus be considered in context of the original CE study population. The microsimulation approach we chose for CAN-TRANce allows us to model the CE study population with realistic variation. In a Markov model such as the Reed model, population characteristics are typically simplified to maintain a reasonable number of nodes and branches. Microsimulation allows representation of the variation in characteristics across individuals in a population. For example, in a Markov model, if the probability of being recurrence free at 10 y is 0.968, each simulated individual is subject to that exact probability of being recurrence free. In a microsimulation model, 0.968 is used to define a distribution for recurrence-free survival, and individuals are assigned different times to recurrence that, when summarized at the population level, equate to a probability of 0.968 at 10 y. One consequence of modeling population variation in this manner is greater uncertainty in results, as seen in case 1 uncertainty intervals compared with those reported in Reed and others. 30 The CANTRANce approach of projecting mortality based on CE studies of intermediate endpoints also has its limitations. As with all models, the quality of the projection will reflect the quality of the input data and the accuracy of the assumptions involved. Study populations, such as the ones used in the 2 case studies, may be small and not representative of major populations of interest. Survival data used to inform model parameters may not be available from populations that resemble the study population. Net survival in particular is not always reported in publications and often must be approximated. In both case studies, we used recurrence-free survival from published studies to approximate the net survival distribution for time from diagnosis to recurrence. This may overestimate the incidence of recurrence. We used relative survival for advanced SEER cases to project the net survival following disease recurrence. So long as survival for recurrent cases is reasonably approximated by survival for newly diagnosed advanced cases, this approximation should be reasonable. Even when available, net disease-specific survival may suffer from informative censoring because of competing events such as other-cause death. Finally, the modeling approach of projecting mortality from intermediate endpoint(s) requires that those endpoints behave as surrogates for mortality. We recognize that endpoints for different cancers may vary in the degree to which they are well-established as surrogates. 32 In our examples, we used disease recurrence as a surrogate for breast cancer mortality, a reasonable approach given the large contribution of recurrent cases to mortality and the low likelihood of cure after recurrence. 33 The model also allows for the inclusion of additional covariates for projecting mortality after the intermediate endpoint. Furthermore, if users extend the model to include quality-of-life and cost data, the quality of those inputs will also affect the accuracy of the results.
CANTRANce also has limitations imposed by its generic form. The simple model structure that makes CANTRANce user-friendly also limits its ability to incorporate more complex features represented in customized models. A primary simplification is the shape of the time to event curve, which is constrained to follow an exponential distribution in CAN-TRANce. While mortality is typically better characterized by more flexible survival curves, specifying these curves would require additional data that may be unavailable to the user. Moreover, any parametric survival curve is likely a simplification of the mortality process. In the case of ER-positive breast cancers, a recent study suggests that the constant mortality hazard implied by the exponential distribution is likely a reasonable approximation to observed survival for these cancers. 34 Other simplifications include the number of key events represented in the disease process and lack of explicit representation of adverse events or heterogeneity in within treatment groups. In the Diagnostics model, we also do not distinguish between treatment recommendations and final treatment decisions, assuming that the recommendations are generally followed. What is gained by losing more complex features is the ability to quickly reuse the model for similar applications without having to build the model from scratch.
The Diagnostics model is a platform for future studies of the value of diagnostic biomarkers for targeting cancer treatment. New diagnostic biomarkers will continue to diffuse into clinical practice before their impact on mortality can be observed. In CAN-TRANce, we offer a blueprint and modeling system for the extrapolation process. We hope that this will empower CE investigators to project the consequences of their interventions beyond intermediate endpoints to long-term endpoints that can inform the adoption of diagnostic biomarkers.
